Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
Navigate: Correlations HPO
There is one clinical trial.
To evaluate the efficacy and safety of azvudine in treatment of COVID-19
Description: (reduction) in viral load from baseline
Measure: Change (reduction) in viral load from baseline Time: On day 7 and 14Description: proportion of subjects change from mild or moderate type to severe type
Measure: proportion of subjects change from mild or moderate type to severe type Time: up to 21 daysDescription: proportion of subjects change from severe type to critical type
Measure: proportion of subjects change from severe type to critical type Time: up to 21 daysDescription: novel coronavirus nucleic acid conversion rate
Measure: novel coronavirus nucleic acid conversion rate Time: up to 21 daysDescription: Novel coronavirus nucleic acid negative conversion time
Measure: Novel coronavirus nucleic acid negative conversion time Time: up to 21 daysDescription: TIme(Days);Proportion(percent)
Measure: The time and proportion of improvement in pulmonary imaging Time: up to 21 daysDescription: TIme(Days);Proportion(percent)
Measure: Time and proportion of temperature return to normal Time: up to 21 daysDescription: TIme(Days);Proportion(percent)
Measure: time and rate of improvement of respiratory symptoms and signs (lung rhones, cough, sputum, sore throat, etc.) Time: up to 21 daysDescription: TIme(Days);Proportion(percent)
Measure: time and rate of improvement of diarrhea, myalgia, fatigue and other symptoms Time: up to 21 daysDescription: Changes of blood oxygen detection index
Measure: Changes of blood oxygen detection index Time: up to 21 daysDescription: Frequency of requirement for supplemental oxygen or non-invasive ventilation
Measure: Frequency of requirement for supplemental oxygen or non-invasive ventilation Time: up to 21 daysDescription: Frequency of adverse events
Measure: Frequency of adverse events Time: up to 21 daysAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports